799 9th Street NW
Suite 210
Washington, DC 20001

T (202) 354 - 2600
vizientinc.com

July 29, 2025

The Honorable Mike Lee
363 Russell Senate Office Building
Washington, DC 20510

The Honorable Ben Ray Luján
498 Russell Senate Office Building
Washington, DC 20510

The Honorable Rand Paul
295 Russell Senate Office Building
Washington, DC 20510

The Honorable Maggie Hassan
324 Hart Russell Senate Office Building
Washington, DC 20510

Dear Senators Lee, Luján, Paul and Hassan,

On behalf of Vizient, Inc., I am pleased to offer again our endorsement for the *Biosimilar Red Tape Elimination Act* (S.1954). This important legislation would increase access to low-cost biosimilars by modernizing the statutory framework for interchangeability and eliminating unnecessary switching studies as a condition for a biosimilar to be deemed interchangeable.

Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65 percent of the nation's acute care providers, including 97 percent of the nation's academic medical centers, and more than 35 percent of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume, enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

The *Biosimilar Red Tape Elimination Act* would take necessary steps to reduce barriers to patients' access to biosimilar drugs. Under current law, biosimilars must receive both FDA approval and a separate determination of interchangeability, creating confusion for prescribers and payers. This legislation would address that challenge by automatically deeming FDA-approved biosimilars as interchangeable with their reference products following a 60-day transition period, while preserving first interchangeability exclusivity. It would also direct the FDA to revise and replace outdated guidance documents to align with the new statutory framework. These updates would reduce unnecessary regulatory burdens, promote greater biosimilar adoption and enhance competition to help lower costs for patients. We are pleased to support this legislation, which will help promote access to life-saving treatments across the country.

Thank you for your ongoing leadership on this issue. Please do not hesitate to contact me at shoshana.krilow@vizientinc.com or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,

Shoshana Krilow
Senior Vice President, Public Policy & Government Relations